Ligand Pharmaceuticals (LGND) EBT Margin (2010 - 2026)

Ligand Pharmaceuticals has disclosed EBT Margin across 17 years of filings, most recently posting 46.9% for Q1 2026.

• EBT Margin for Q1 2026 came in at 46.9%, up 6379.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 67.36% (up 15613.0% YoY), and the FY2025 annual result was 59.29%, up 5779.0% from the prior year.
• EBT Margin came in at 46.9% for Q1 2026 at Ligand Pharmaceuticals, down from 95.16% in the prior quarter.
• In the past five years, EBT Margin ranged from a high of 366.22% in Q1 2024 to a low of 157.45% in Q2 2024.
• The 5-year median for EBT Margin is 17.28% (2022), against an average of 24.21%.
• Across the five-year window, EBT Margin jumped 23994 bps in 2024 and sank 47691 bps in 2025, its largest moves.
• Ligand Pharmaceuticals' EBT Margin stood at 47.91% in 2022, then advanced by 27 bps to 60.84% in 2023, then tumbled by 250 bps to 91.56% in 2024, then soared by 204 bps to 95.16% in 2025, then tumbled by 149 bps to 46.9% in 2026.
• The last three EBT Margin figures came in at 46.9% (Q1 2026), 95.16% (Q4 2025), and 122.24% (Q3 2025), per Business Quant data.